YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma - PubMed
3 days ago
- #multiple-myeloma
- #trispecific-antibody
- #immunotherapy
- YMN-V115 is a novel humanized trispecific antibody targeting BCMA, GPRC5D, and CD3 for relapsed/refractory multiple myeloma (MM).
- The antibody is designed in a 1+1+1 format to enhance tumor-specific T cell engagement and reduce off-tumor toxicity.
- YMN-V115 demonstrated superior cytotoxic activity in preclinical models, outperforming bispecific antibodies.
- It maintains efficacy under soluble BCMA-saturated conditions, showing resistance to decoy inhibition.
- The trispecific antibody addresses antigenic heterogeneity by targeting both BCMA+ and GPRC5D+ tumor subsets.
- Preclinical findings support YMN-V115 as a promising next-generation therapy for MM.